272 related articles for article (PubMed ID: 26875157)
41. Screening and prevention of hereditary gynecologic cancers.
Kehoe SM; Kauff ND
Semin Oncol; 2007 Oct; 34(5):406-10. PubMed ID: 17920895
[TBL] [Abstract][Full Text] [Related]
42. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
43. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
Rabban JT; Krasik E; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Dec; 33(12):1878-85. PubMed ID: 19898224
[TBL] [Abstract][Full Text] [Related]
44. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H
J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532
[TBL] [Abstract][Full Text] [Related]
45. The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance.
Neusser S; Lux B; Barth C; Pahmeier K; Rhiem K; Schmutzler R; Engel C; Wasem J; Huster S; Dabrock P; Neumann A
Curr Med Res Opin; 2019 Dec; 35(12):2103-2110. PubMed ID: 31394049
[No Abstract] [Full Text] [Related]
46. Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer.
AlHilli MM; Al-Hilli Z
J Minim Invasive Gynecol; 2019 Feb; 26(2):253-265. PubMed ID: 30240898
[TBL] [Abstract][Full Text] [Related]
47. [Prophylactic mastectomy in women at high risk for breast cancer: indications and options].
Scheufler O; Fritschen Uv
Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):239-47. PubMed ID: 18716986
[TBL] [Abstract][Full Text] [Related]
48. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
[TBL] [Abstract][Full Text] [Related]
50. The frequency and outcome of breast cancer risk-reducing surgery in Finnish BRCA1 and BRCA2 mutation carriers.
Koskenvuo L; Svarvar C; Suominen S; Aittomäki K; Jahkola T
Scand J Surg; 2014 Mar; 103(1):34-40. PubMed ID: 24177987
[TBL] [Abstract][Full Text] [Related]
51. Georgia Primary Care Providers' Knowledge of Hereditary Breast and Ovarian Cancer Syndrome.
Nair N; Bellcross C; Haddad L; Martin M; Matthews R; Gabram-Mendola S; Crane B; Meaney-Delman D
J Cancer Educ; 2017 Mar; 32(1):119-124. PubMed ID: 26637472
[TBL] [Abstract][Full Text] [Related]
52. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
53. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
54. Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes.
Nakonechny QB; Gilks CB
Surg Pathol Clin; 2016 Jun; 9(2):189-99. PubMed ID: 27241103
[TBL] [Abstract][Full Text] [Related]
55. Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.
Casey MJ; Salzman TA
Linacre Q; 2018 Aug; 85(3):225-240. PubMed ID: 30275608
[TBL] [Abstract][Full Text] [Related]
56. Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
Menkiszak J; Chudecka-Głaz A; Gronwald J; Cymbaluk-Płoska A; Celewicz A; Świniarska M; Wężowska M; Bedner R; Zielińska D; Tarnowska P; Jakubowicz J; Kojs Z
J Ovarian Res; 2016 Feb; 9():11. PubMed ID: 26928677
[TBL] [Abstract][Full Text] [Related]
57. Hereditary breast cancer: an update on risk assessment and genetic testing in 2015.
Stuckey AR; Onstad MA
Am J Obstet Gynecol; 2015 Aug; 213(2):161-5. PubMed ID: 25747548
[TBL] [Abstract][Full Text] [Related]
58. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
59. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
[TBL] [Abstract][Full Text] [Related]
60. Familial Gastrointestinal Stromal Tumor with Germline
Sekido Y; Ohigashi S; Takahashi T; Hayashi N; Suzuki K; Hirota S
Anticancer Res; 2017 Mar; 37(3):1425-1431. PubMed ID: 28314314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
